Generics 'Express Lane' Urged To Rival High-Priced Drugs
This article was originally published in Scrip
Executive Summary
Even though the review timeline for abbreviated new drug applications (ANDAs) for generic medicines is expected to drop to 10 months beginning Oct. 1, some lawmakers are calling for a faster way to get copycat products on the US market when there's no competition – especially in cases where a company has significantly jacked up the price of an older drug.